Policy
The $1.2 trillion budget package will now move to the Senate, which is expected to hold a vote next week.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former US Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
KB105 is a new gene therapy candidate engineered with a Transglutaminase-1 (TGM1) gene construct to treat TGM1 deficient autosomal recessive congenital ichthyosis
June is turning out to be a busy month for approvals for the U.S. Food and Drug Administration. The agency has a slate of PDUFA dates this week, including two for Merck alone. Here’s a look.
The stool sample used in the experimental procedure was not properly tested, the FDA said.
Amarantus Bioscience Holdings, Inc. announced that subsidiary MANF Therapeutics was issued U.S. Patent No. 10,195,251 entitled ‘Methods of Treatment for Retinal Diseases Using MANF and CDNF’ that covers the use of mesencephalic astrocyte-derived neurotrophic factor or cerebral dopamine neurotrophic factor as a treatment for various ophthalmic disorders, including inherited retinal disorders, age-related macular degeneration and glaucoma.
The pilot program aims to develop an electronic system to identify and trace certain prescription drugs as they are distributed within the United States.
Efforts undertaken by state and local leaders across the five states that make up Pharm Country have led to a boost in business, which is good news for applicants seeking a new position.
The International Biofilm Summit, addressing the main threat to food contamination, seizes the opportunity of its third edition on 23-24 October to take it to the next level.
Complaint Cites Multiple Violations of Food, Drug, and Cosmetic Act
Novartis was alleged to have held about 80,000 sham events where doctors were wined and dined in order to boost sales of key medications.
BIO’s Jim Greenwood hailed the executive order as an important decision to foster biology-driven solutions to nutrition and improving crop yield.